Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company with an active flow of corporate, clinical, and financial news. The company develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses, and its communications frequently highlight progress in these areas. Investors following ANIP news can track how the Rare Disease segment, including products such as ILUVIEN and Purified Cortrophin Gel, contributes to the company’s growth alongside its generics and branded drug portfolios.
News updates for ANI often cover financial results and guidance, including quarterly earnings releases, adjusted non-GAAP metrics, and full-year outlooks. Press releases and related Form 8-K filings provide detail on net revenues by segment, the performance of key products, and management’s commentary on business trends. These disclosures also outline how Rare Disease revenues, particularly from Cortrophin Gel and ILUVIEN, compare with contributions from Generics and Brands.
ANIP news also includes clinical and medical developments, such as results from the NEW DAY clinical trial of ILUVIEN in diabetic macular edema and their presentation at major ophthalmology and retina meetings. The company reports on initiatives like the FutureVision Advisory Council, a group of retina and uveitis specialists formed to help guide its ophthalmology and retina franchise. Updates on Phase 4 trials, label transitions, and adoption trends for ILUVIEN and related products are also featured.
In addition, ANI regularly announces corporate and governance updates, including board transitions and leadership roles, as well as participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Jefferies, H.C. Wainwright, and Morgan Stanley. These events often involve presentations or fireside chats where management discusses strategy, the transformation toward a rare disease–focused profile, and capital allocation priorities.
By monitoring ANIP news, readers can follow developments across rare disease therapeutics, generics, branded products, clinical research, and capital markets activity, all of which shape the company’s trajectory.
ANI Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) and launched Estradiol Gel, 0.06%, a generic version of EstroGel® Gel, 0.06%. The product enters a market with annual sales of approximately $16.7 million, according to August 2024 IQVIA data. This launch represents another -competition product in ANI's portfolio, aimed at ensuring accessibility for patients and customers.
ANI Pharmaceuticals (ANIP) announced its upcoming presentation of new pre-clinical data on membranous nephropathy (MN) research at the American Society of Nephrology Kidney Week 2024 in San Diego, October 23-27. The company will showcase two poster presentations focusing on THSD7A-associated membranous nephropathy and melanocortin therapy's protective effects.
Chief Medical Officer Dr. Mary Pao highlighted the significance of their research in understanding melanocortin receptors' role in nephrotic syndrome. The presentations will be delivered by lead author Jing Liu, with sessions scheduled for October 25 and 26.
ANI Pharmaceuticals has announced the FDA approval and launch of Ketoconazole Shampoo, 2%, a generic version of Nizoral®. This approval marks another competition product for ANI, aligning with their strategic priority to launch new products addressing patient needs. The company's R&D team has been credited for this achievement.
Nikhil Lalwani, President and CEO of ANI, expressed pride in the approval and commercialization of the product. According to IQVIA data from July 2024, the U.S. annual sales for Ketoconazole Shampoo, 2% total approximately $69.2 million. This launch represents ANI's entry into a significant market segment, potentially boosting the company's revenue and market position in the pharmaceutical industry.
ANI Pharmaceuticals (ANIP) has completed its acquisition of Alimera Sciences, strengthening its Rare Disease segment. The deal adds approximately $105 million in 2024 revenue on a pro forma basis and expands ANI's footprint to 20 countries. Key points include:
1. Addition of two commercial assets: ILUVIEN® and YUTIQ® with growth potential in ophthalmology
2. Expected to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025
3. New capital structure reducing interest expense by approximately $39 million annually
4. Expansion of Rare Disease segment to ~45% of pro forma 2024 revenues
5. Potential for accelerated growth of Cortrophin Gel in ophthalmology
ANI maintains its 2024 financial guidance for the standalone company based on continued momentum across Purified Cortrophin® Gel and Generics.
ANI Pharmaceuticals (Nasdaq: ANIP) has initiated closing logistics for its previously announced acquisition of Alimera Sciences (Nasdaq: ALIM). The company expects to complete and announce the closing of the acquisition today, September 16, 2024, subject to the satisfaction or waiver of any remaining customary closing conditions. This strategic move signifies a significant expansion for ANI Pharmaceuticals, potentially enhancing its market position and product portfolio. The acquisition of Alimera Sciences, a company known for its focus on retinal diseases, could bring new opportunities and synergies to ANI's existing pharmaceutical operations.
ANI Pharmaceuticals (Nasdaq: ANIP) has launched Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, 6.25 mg/15 mg per 5 mL. This marks the company's 14th new product launch in 2024, contributing to strong growth in its Generics business. The timing of the launch is strategic, coinciding with the upcoming cough and cold season.
According to IQVIA data from July 2024, the U.S. annual sales for this oral solution total approximately $42.6 million. This launch aligns with ANI's strategy to expand its product portfolio and capitalize on market opportunities in the pharmaceutical sector.
ANI Pharmaceuticals (NASDAQ: ANIP) and Alimera Sciences (NASDAQ: ALIM) have announced the closing date for their merger. The transaction is scheduled to close before the market opens on Monday, September 16, 2024. This announcement follows the previously disclosed Merger Agreement between the two companies. The merger represents a significant development in the pharmaceutical industry, potentially combining the strengths and resources of both entities.
ANI Pharmaceuticals (Nasdaq: ANIP) has provided an update on the status of its previously announced acquisition of Alimera Sciences (Nasdaq: ALIM). The company acknowledges Alimera's press release and states that it continues to work in good faith toward closing the acquisition. ANI attributes any delay to ongoing discussions regarding closing conditions, which it expects to resolve promptly. The update suggests that the acquisition process is still active, but certain details are being finalized before the transaction can be completed.
Alimera Sciences (Nasdaq: ALIM) has filed a lawsuit against ANI Pharmaceuticals (Nasdaq: ANIP) in the Delaware Court of Chancery to enforce the previously announced merger agreement. The legal action aims to compel ANI to close the merger transaction and honor its contractual obligations. Alimera shareholders approved the merger on September 4, fulfilling the last requirement for closing. The company states that it has met all its obligations, but ANI has failed to close on time. Alimera believes the merger offers compelling value for shareholders and is committed to completing the transaction. The lawsuit specifically requests the Court to require ANI to comply with its obligations to finalize the merger as outlined in the Agreement and Plan of Merger dated June 21, 2024.
ANI Pharmaceuticals has successfully closed its offering of $316.25 million in 2.25% convertible senior notes due 2029. The offering, initially set at $250 million, was upsized to $275 million with an additional $41.25 million exercised by initial purchasers. Net proceeds are approximately $306.8 million. ANI plans to use $40.6 million for capped call transactions and the remainder to repay its existing senior secured term loan facility. The company also entered a new senior secured credit agreement with a $325 million delayed draw term loan facility and a $75 million revolving facility. The capped call transactions are expected to reduce potential dilution and offset potential cash payments upon note conversion.